Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.77 |
| ▸ | PGR | P06401 | 6/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | IL5 | P05113 | 1/20 | 0.77 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.77 |
| ▸ | AR | P10275 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | MMP9 | P14780 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | THPO | P40225 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965919 | 1.00 | NR3C1 (0.77) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL21153523 | 1.00 | NR3C1 (0.77) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL21153755 | 1.00 | NR3C1 (0.77) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL30987798 | 0.94 | NR3C1 (0.77) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL5396842 | 0.93 | NR3C1 (0.81) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL19583464 | 0.93 | NR3C1 (0.76) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL3305265 | 0.93 | NR3C1 (0.76) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL18051174 | 0.93 | NR3C1 (0.76) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL19583457 | 0.93 | NR3C1 (0.76) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL4448853 | 0.92 | NR3C1 (0.82) | NR3C1PGRHIF1ACYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118955604-A | Steroid compounds and antibody conjugates thereof | 里珍纳龙药品有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-112004557-B | Steroid compounds and antibody conjugates thereof | 里珍纳龙药品有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| WO-2019136487-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 223/4885HIF1A 3323/4885 |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 223/4885HIF1A 3323/4885 |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 223/4885HIF1A 3323/4885 |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | NR3C1 1628/4885PGR 3140/4885HIF1A 2218/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 223/4885HIF1A 3323/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR3C1 1628/4885PGR 3140/4885HIF1A 2218/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR3C1 1628/4885PGR 3140/4885HIF1A 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.